Press release from Sen. Mike Crapo: Crapo, Republican Senators Seek Explanation, Urge Reconsideration of Changes to Kratom-Derived Scheduling
Press release from Sen. Mike Crapo, in his office's own words; not the paper's reporting.
Washington, D.C.--U.S. Senator Mike Crapo (R-Idaho) joined Senate Judiciary Committee Chairman Chuck Grassley (R-Iowa) and six Republican Senators in a letter urging the Drug Enforcement Administration (DEA) and the Food and Drug Administration (FDA) to explain and reconsider proposed changes to the emergency scheduling order for semi-synthetic, kratom-derived substances, including 7-hydroxymitragynine (7-OH) and mitragynine pseudoindoxyl (MP).
In July 2026, the DEA proposed placing 7-OH above a 0.05 percent threshold in Schedule I of the Controlled Substances Act and subsequently issued an order placing three semi-synthetic kratom-related substances, including MP, in Schedule I. However, in October, the DEA reversed course, issuing a revised proposal that doubled the original threshold established for 7-OH and removed MP from Schedule I. October’s decision would allow both chemicals to be present in over-the-counter kratom products at levels higher than those found naturally in the kratom plant.
Specifically, the Senators’ letter requests the DEA and FDA: Provide Congress the scientific and medical evaluations the agencies relied on to set a higher threshold limit for 7-OH; Explain how a higher threshold for 7-OH better protects American families than the original, lower threshold; and Reconsider the updated threshold level for 7-OH and place kratom substances containing any amount of MP in Schedule I.
Crapo and Grassley are joined on the letter by Senators Jim Risch (R-Idaho), Susan Collins (R-Maine), Rick Scott (R-Florida), Bill Cassidy (R-Louisiana), Jerry Moran (R-Kansas) and Shelley Moore Capito (R-West Virginia).
The Idaho Department of Health and Welfare reported 83 deaths from kratom-related overdoses from 2020 to 2024.
Read the original: Crapo, Republican Senators Seek Explanation, Urge Reconsideration of Changes to Kratom-Derived Scheduling (Nov. 18, 2026)